DBCO-PEG4-Val-Cit-PAB-OH CAS:2226472-27-9 is a type of small molecule drug that is used in the treatment of cancer. It is composed of several functional groups, including a DBCO group, a polyethylene glycol (PEG) spacer, a valine-citrulline dipeptide, a p-aminobenzyloxycarbonyl (PAB) group, and a carboxylic acid group.
The DBCO group is a type of functional group that can be used to react with other molecules in a process called click chemistry. The PEG spacer is used to improve the solubility and stability of the drug in solution, allowing it to be more easily administered to patients. The valine-citrulline dipeptide is a type of peptide that has been shown to have anti-tumor activity in some types of cancer cells. The PAB group is used as a protecting group for the amino group of the lysine residue in the dipeptide. The carboxylic acid group is important for the chemical reactivity and solubility of the compound.
In terms of its mechanism of action, DBCO-PEG4-Val-Cit-PAB-OH works by selectively targeting and binding to cancer cells that express a specific cell surface receptor. Once bound to the cancer cell, the drug is taken up by the cell and induces apoptosis, or programmed cell death. This targeted approach can help to reduce the side effects of chemotherapy and improve outcomes for patients with cancer. For those engaged in the development and research of such targeted therapies, understanding the role of DBCO NHS and DBCO click chemistry is vital.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.